NCT Number,Study Title,Study URL,Acronym,Study Status,Brief Summary,Study Results,Conditions,Interventions,Primary Outcome Measures,Secondary Outcome Measures,Other Outcome Measures,Sponsor,Collaborators,Sex,Age,Phases,Enrollment,Funder Type,Study Type,Study Design,Other IDs,Start Date,Primary Completion Date,Completion Date,First Posted,Results First Posted,Last Update Posted,Locations,Study Documents
NCT03417102,A Study of Fitusiran (ALN-AT3SC) in Severe Hemophilia A and B Patients With Inhibitors,https://clinicaltrials.gov/study/NCT03417102,ATLAS-INH,COMPLETED,"The purpose of this study was to determine the frequency of bleeding episodes in participants receiving fitusiran as prophylactic treatment of hemophilia compared to participants who were assigned to continue with their regular medication. In addition, the study assessed safety, quality of life, pharmacodynamics (PD), and pharmacokinetics (PK).",YES,Hemophilia A|Hemophilia B,DRUG: fitusiran|DRUG: Bypassing agents,"Estimated Annualized Bleeding Rate (ABR) for Treated Bleeds During the Efficacy Period, ABR for a participant during efficacy period (EP) was defined as annualized number of bleeding episodes during EP annualized to a 1-year interval of time. Treated Bleeding episode: any occurrence of hemorrhage that required administration of BPA or factor. It started from first sign of a bleed and ended no more than 72 hours after last treatment for bleed, within which any symptoms of bleeding at same location or injections less than or equal to 72 hours apart were considered the same bleeding episode. EP was defined as time duration starting from Day 29 when antithrombin (AT) lowering capacity of fitusiran had achieved therapeutic target range to the earliest of (Day 246 or last day of bleeding follow up) (maximum duration of EP: from Day 29 to Day 246). This outcome measure (OM) represents estimated results (i.e., results received by applying negative binomial \[NB\] regression model on data collected during EP)., From Day 29 up to Day 246 or up to the last day of bleeding follow up (any day up to Day 246), whichever was the earliest|Observed Annualized Bleeding Rate (ABR) for Treated Bleeds During the Efficacy Period, ABR for a participant during EP was defined as annualized number of bleeding episodes during EP annualized to a 1-year interval of time. ABR= number of bleeding episodes during EP divided by total number of days during EP\*365.25. A bleeding episode was defined as any occurrence of hemorrhage that required administration of BPA or factor. It started from the first sign of a bleed and ended no more than 72 hours after the last treatment for the bleed, within which any symptoms of bleeding at the same location or injections less than or equal to 72 hours apart were considered the same bleeding episode. EP was defined as time duration starting from Day 29 when the AT lowering capacity of fitusiran had achieved therapeutic target range to the earliest of (Day 246 or the last day of bleeding follow up) (maximum duration of EP: from Day 29 to Day 246). This OM represents observed results (i.e., descriptive statistics values based on the data which was collected during EP)., From Day 29 up to Day 246 or up to the last day of bleeding follow up (any day up to Day 246), whichever was the earliest","Estimated Annualized Bleeding Rate (ABR) for Treated Bleeds During the Treatment Period, ABR for a participant during treatment period (TP) was defined as annualized number of bleeding episodes during TP annualized to a 1-year interval of time. Bleeding episode: any occurrence of hemorrhage that required administration of BPA or factor. It started from first sign of a bleed and ended no more than 72 hours after last treatment for bleed, within which any symptoms of bleeding at same location or injections less than or equal to 72 hours apart were considered the same bleeding episode. TP was sum of onset period (first 28 days after first dose of fitusiran) and EP (starting on Day 29 when AT lowering capacity of fitusiran had achieved therapeutic target range to earliest of \[Day 246 or last day of bleeding follow up\])(maximum duration of TP: from Day 1 to Day 246). This OM represents estimated results (i.e., results received by applying NB regression model on data collected during TP)., From Day 1 up to Day 246 or up to the last day of bleeding follow up (any day up to Day 246), whichever was the earliest|Observed Annualized Bleeding Rate (ABR) for Treated Bleeds During the Treatment Period, ABR for a participant during TP was defined as annualized number of bleeding episodes during TP annualized to a 1-year interval of time. ABR= number of bleeding episodes during TP divided by total number of days during TP\*365.25. Bleeding episode: any occurrence of hemorrhage that required administration of BPA or factor. It started from the first sign of a bleed and ended no more than 72 hours after last treatment for bleed, within which any symptoms of bleeding at the same location or injections less than or equal to 72 hours apart were considered the same bleeding episode. TP was sum of onset period (first 28 days after the first dose of fitusiran) and EP (starting on Day 29 when AT lowering capacity of fitusiran had achieved therapeutic target range to the earliest of \[Day 246 or the last day of bleeding follow up\]) (maximum duration of TP: from Day 1 to Day 246). This OM represents observed results (i.e., descriptive statistics values based on data collected during TP)., From Day 1 up to Day 246 or up to the last day of bleeding follow up (any day up to Day 246), whichever was the earliest|Estimated Annualized Spontaneous Bleeding Rate for Treated Bleeds During Efficacy Period, Annualized spontaneous bleeding rate for a participant during EP was defined as annualized number of spontaneous bleeding episodes during EP annualized to a 1-year interval of time. Spontaneous bleeding episode was bleeding event that occurred for no apparent or known reason, particularly into joints, muscles, and soft tissues. It started from first sign of a bleed and ended no more than 72 hours after last treatment for the bleed, within which any symptoms of bleeding at the same location or injections less than or equal to 72 hours apart were considered the same bleeding episode. EP was defined as time duration starting from Day 29 when AT lowering capacity of fitusiran had achieved therapeutic target range to the earliest of (Day 246 or last day of bleeding follow up) (maximum duration of EP: from Day 29 to Day 246). This OM represents estimated results (i.e., results received by applying NB regression model on data collected during EP)., From Day 29 up to Day 246 or up to the last day of bleeding follow up (any day up to Day 246), whichever was the earliest|Observed Annualized Spontaneous Bleeding Rate for Treated Bleeds During the Efficacy Period, ABR for participant during EP was defined as annualized number of spontaneous bleeding episodes during EP annualized to a 1-year interval of time. ABR=number of treated spontaneous bleeding episodes during EP divided by total number of days during EP\*365.25. Spontaneous bleeding episode was bleeding event that occurred for no apparent or known reason, into joints, muscles, and soft tissues. It started from the first sign of a bleed and ended no more than 72 hours after the last treatment for bleed, within which any symptoms of bleeding at the same location or injections less than or equal to 72 hours apart were considered the same bleeding episode. EP: time duration starting from Day 29 when the AT lowering capacity of fitusiran had achieved therapeutic target range to earliest of (Day 246 or the last day of bleeding follow up) (maximum duration of EP: from Day 29 to Day 246). This OM represents observed results (i.e., descriptive statistics values based on data collected during EP)., From Day 29 up to Day 246 or up to the last day of bleeding follow up (any day up to Day 246), whichever was the earliest|Estimated Annualized Joint Bleeding Rate for Treated Bleeds During the Efficacy Period, Annualized joint bleeding rate for a participant during EP was defined as annualized number of bleeding episodes during EP annualized to a 1-year interval of time. Joint bleeding episode was characterized by an unusual sensation in the joint (""aura"") in combination with 1) increasing swelling or warmth over the skin, joint, 2) increased pain, or 3) progressive loss of range of motion or difficulty in using the limb as compared with Baseline. It started from first sign of a bleed and ended no more than 72 hours after last treatment for the bleed. EP was defined as time duration starting from Day 29 when the AT lowering capacity of fitusiran had achieved therapeutic target range to the earliest of (Day 246 or the last day of bleeding follow up) (maximum duration of EP: from Day 29 to Day 246). This OM presents estimated results (i.e., results received by applying NB regression model on data collected during EP)., From Day 29 up to Day 246 or up to the last day of bleeding follow up (any day up to Day 246), whichever was the earliest|Observed Annualized Joint Bleeding Rate for Treated Bleeds During the Efficacy Period, Annualized joint bleeding rate for participant during EP was defined as annualized number of joint bleeding episodes during EP annualized to 1-year interval of time. ABR= number of treated joint bleeding episodes during EP divided by total number of days during EP\*365.25. A joint bleeding episode was characterized by an unusual sensation in joint (""aura"") in combination with 1) increasing swelling or warmth over skin, joint, 2) increased pain, or 3) progressive loss of range of motion or difficulty in using limb as compared with Baseline. It started from first sign of a bleed and ended no more than 72 hours after the last treatment for the bleed. EP: time duration starting from Day 29 when the AT lowering capacity of fitusiran had achieved therapeutic target range to the earliest of (Day 246 or last day of bleeding follow up) (maximum duration of EP: from Day 29 to Day 246). This OM presents observed results (i.e., descriptive statistics values based on data collected during EP)., From Day 29 up to Day 246 or up to the last day of bleeding follow up (any day up to Day 246), whichever was the earliest|Health-related Quality of Life (HRQOL): Change From Baseline in Haemophilia Quality of Life Questionnaire for Adults (Haem-A-QOL) Physical Health Domain Score at Month 9, Haem-A-QoL: participant-reported questionnaire designed for adult participants (\>=17 years of age) with hemophilia; and consisted of 46 items comprising 10 domains (physical health, feelings, view of yourself, sports and leisure, work and school, dealing with hemophilia, treatment, future, family planning, partnership and sexuality). Items were rated along five response options: never, rarely, sometimes, often, or all the time. Change from baseline in physical Health domain score was reported in this outcome measure. Raw score for physical health domain were transformed to a scale ranged from 0 to 100, where lower scores denoted better physical health., Baseline (Day 1), Month 9|Health-related Quality of Life (HRQOL): Change From Baseline in Haem-A-QOL Total Score at Month 9, Haem-A-QoL: participant-reported questionnaire designed for adult participants (\>=17 years of age) with hemophilia; and consisted of 46 items comprising 10 domains (physical health, feelings, view of yourself, sports and leisure, work and school, dealing with hemophilia, treatment, future, family planning, partnership and sexuality). Items were rated along five response options: never, rarely, sometimes, often, or all the time. Raw score for each domain were transformed to a scale ranged from 0 to 100, where lower scores denoted better health. Haem-A-QoL Total Score was average of all domain scores and ranged from 0 to 100, where lower scores denoted better quality of life., Baseline (Day 1), Month 9|Estimated Annualized Bleeding Rate (ABR) for Treated Bleeds During the Onset Period, ABR was annualized number of bleeding episodes during onset period per participant annualized to a 1-year interval of time. A treated bleeding episode was defined as any occurrence of hemorrhage that may required administration of BPA or factor. It started from the first sign of a bleed and ended no more than 72 hours after the last treatment for the bleed, within which any symptoms of bleeding at the same location or injections less than or equal to 72 hours apart were considered the same bleeding episode. The onset period was defined as time interval from Day 1 to the earlier of Day 28 or the last day of bleeding follow up. This OM represents estimated results (i.e., results received by applying NB regression model on data collected during onset period)., From Day 1 up to Day 28 or up to the last day of bleeding follow up (any day up to Day 28), whichever was the earliest|Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Treatment-Emergent Serious Adverse Events (TESAEs), An adverse Event (AE) was defined as any untoward medical occurrence in a participant who received study drug which did not necessarily have a causal relationship with the treatment. Treatment emergent AEs were defined as any AE with onset date after first dose of fitusiran in the fitusiran prophylaxis arm or after Day 1 visit in the BPA on-demand arm. A Serious AE (SAE) was defined as any untoward medical occurrence that at any dose: resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability or incapacity, was a congenital anomaly or birth defect, or was a medically important event., From Baseline (Day 1) up to 15 months (i.e. 9 months treatment period + 6-months follow-up)",,"Genzyme, a Sanofi Company",,MALE,"CHILD, ADULT, OLDER_ADULT",PHASE3,60,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,EFC14768|2016-001463-36|ALN-AT3SC-003,2018-02-14,2020-11-25,2021-06-23,2018-01-31,2021-12-21,2022-03-28,"Investigational Site Number 0117, Phoenix, Arizona, 85016, United States|Investigational Site Number 0139, Los Angeles, California, 90027, United States|Investigational Site Number 0135, Orange, California, 92868, United States|Investigational Site Number 0137, San Diego, California, 92123, United States|Investigational Site Number 0128, Gainesville, Florida, 32610, United States|Investigational Site Number 0115, Jacksonville, Florida, 32207, United States|Investigational Site Number 0105, Miami, Florida, 33136, United States|Investigational Site Number 0103, Tampa, Florida, 33607, United States|Investigational Site Number 0119, New Orleans, Louisiana, 70112, United States|Investigational Site Number 0136, Baltimore, Maryland, 21205, United States|Investigational Site Number 0111, Las Vegas, Nevada, 89135, United States|Investigational Site Number 0104, Philadelphia, Pennsylvania, 19104-5127, United States|Investigational Site Number 6101, Camperdown, 2050, Australia|Investigational Site Number 6104, Clayton, 3168, Australia|Investigational Site Number 1102, Montreal, H1T 2M4, Canada|Investigational Site Number 8604, Beijing, 100045, China|Investigational Site Number 8602, Guangzhou, 510515, China|Investigational Site Number 8605, Hangzhou, 310003, China|Investigational Site Number 8603, Shanghai, 200025, China|Investigational Site Number 8601, Tianjin, 300020, China|Investigational Site Number 3303, Lyon, 69677, France|Investigational Site Number 3301, Rouen, 76038, France|Investigational Site Number 4905, Frankfurt Am Main, 60590, Germany|Investigational Site Number 4906, Leipzig, 4103, Germany|Investigational Site Number 9102, Bangalore, 560034, India|Investigational Site Number 9108, India, India|Investigational Site Number 9104, Jaipur, 302017, India|Investigational Site Number 9106, Lucknow, 226003, India|Investigational Site Number 9103, Pune, 411001, India|Investigational Site Number 9111, Pune, 411004, India|Investigational Site Number 9105, Vellore, 632004, India|Investigational Site Number 3901, Florence, 50134, Italy|Investigational Site Number 3904, Padua, 35128, Italy|Investigational Site Number 8110, Japan, Japan|Investigational Site Number 8103, Kita Kyushu-Shi, Japan|Investigational Site Number 8202, Daejeon, 35233, Korea, Republic of|Investigational Site Number 8203, Seoul, 3722, Korea, Republic of|Investigational Site Number 8204, Seoul, Korea, Republic of|Investigational Site Number 6003, Kota Kinabalu, 88586, Malaysia|Investigational Site Number 6004, Malaysia, Malaysia|Investigational Site Number 2701, Parktown, 2193, South Africa|Investigational Site Number 2703, Polokwane, 699, South Africa|Investigational Site Number 2702, Port Elizabeth, 6001, South Africa|Investigational Site Number 3402, Madrid, 28046, Spain|Investigational Site Number 8803, Changhua, 500, Taiwan|Investigational Site Number 8801, Taipei, 110, Taiwan|Investigational Site Number 8804, Taiwan, Taiwan|Investigational Site Number 8805, Taiwan, Taiwan|Investigational Site Number 9002, Adana, ?01130, Turkey|Investigational Site Number 9004, Akdeniz, 07059, Turkey|Investigational Site Number 9001, Ankara, 06100, Turkey|Investigational Site Number 9005, Istanbul, 34093, Turkey|Investigational Site Number 9003, Izmir, 35100, Turkey|Investigational Site Number 9006, Turkey, Turkey|Investigational Site Number 8003, Kyiv, 01135, Ukraine|Investigational Site Number 8001, Kyiv, 04060, Ukraine|Investigational Site Number 8002, Lviv, 79044, Ukraine|Investigational Site Number 4407, London, E1 2ES, United Kingdom","Study Protocol, https://cdn.clinicaltrials.gov/large-docs/02/NCT03417102/Prot_000.pdf|Statistical Analysis Plan, https://cdn.clinicaltrials.gov/large-docs/02/NCT03417102/SAP_001.pdf"
